Anderlecht

• A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-s … Ended recruitment
  2023-503868-16-00 5 2022-02-14 Small-Cell Lung Cancer (SCLC)
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 Expression Ended recruitment
  2024-510655-36-00 7 2022-02-01 Advanced Malignancies Associated with EphA2 Expression
• FIRST-IN-HUMAN STUDY OF IPH5301 TREATMENT ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS Ended recruitment
  2023-504605-36-00 1 2022-01-21 Dose escalation cohort: advanced and/or metastatic cancer car-cinoma o
• OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma … Ended recruitment
  2024-512634-15-00 9 2022-01-05 Patients with untreated mantle cell lymphoma
• Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL tri … Ended recruitment
  2023-508242-18-00 6 2021-12-21 Crohn's disease
• A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance … Ended recruitment
  2023-509133-39-00 5 2021-11-29 Hormone receptor positive, HER2-negative advanced breast cancer
• A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr … Ended recruitment
  2023-508248-23-00 5 2021-11-26 Non-alcoholic steatohepatitis (NASH)
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended recruitment
  2023-508838-33-00 5 2021-10-06 Chronic Myeloid Leukemia
• EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER … Ended recruitment
  2023-506786-63-00 5 2021-09-30 Breast Cancer
• A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Ended recruitment
  2023-508723-12-00 5 2021-09-27 gastroenteropancreatic neuroendocrine tumors
• An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic … Ended recruitment
  2024-514905-79-00 9 2021-09-17 Metastatic pancreatic ductal adenocarcinoma
• An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn's disease previously included in the loss … Ended recruitment
  2024-514326-23-00 11 2021-09-10 Crohn's disease
• A trial to learn how safe rilvegostomig (AZD2936) is, how it moves throughout the body over time, and how well it works in adults with advan … Ended recruitment
  2023-508262-15-00 7 2021-09-09 Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung C
• Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC Ended recruitment
  2024-514461-19-00 9 2021-09-09 Solid Tumors
• A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended recruitment
  2023-506368-14-00 5 2021-09-07 Systemic lupus erythematosus (SLE)
• DALY 2-EU Ended recruitment
  2023-506270-13-00 4 2021-07-27 Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)
• A study to investigate the efficacy and safety of trastuzumab deruxtecan in patients With or Without Brain Metastasis Who Have Previously-Tr … Ended recruitment
  2024-510588-53-00 11 2021-06-10 Treatment of patients with HER2-positive breast cancer with or without
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER … Ended recruitment
  2023-503995-26-00 5 2021-05-11 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
• Once-daily inhaled molgramostim nebulizer solution in aPAP Ended recruitment
  2024-511052-41-00 5 2021-05-10 Autoimmune Pulmonary Alveolar Proteinosis
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended recruitment
  2024-510620-39-00 5 2021-04-19 Advanced RCC with clear cell component
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended recruitment
  2023-506962-30-00 5 2021-03-29 Non-alcoholic steatohepatitis (NASH)
• A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III r … Ended recruitment
  2024-516554-22-00 4 2021-03-29 Locally-advanced stage II-III rectal cancer

Showing 289–312 of 445 trials